Ferrer-Gómez et al., 2021 - Google Patents
Late cardiac pathology in severe covid-19. A postmortem series of 30 patientsFerrer-Gómez et al., 2021
View HTML- Document ID
- 6279533589187501754
- Author
- Ferrer-Gómez A
- Pian-Arias H
- Carretero-Barrio I
- Navarro-Cantero A
- Pestaña D
- de Pablo R
- Zamorano J
- Galán J
- Pérez-Mies B
- Ruz-Caracuel I
- Palacios J
- Publication year
- Publication venue
- Frontiers in cardiovascular medicine
External Links
Snippet
The role of SARS-CoV-2 as a direct cause in the cardiac lesions in patients with severe COVID-19 remains to be established. Our objective is to report the pathological findings in cardiac samples of 30 patients who died after a prolonged hospital stay due to Sars-Cov-2 …
- 230000000747 cardiac effect 0 title abstract description 30
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gąsecka et al. | Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment | |
| Buja et al. | The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities | |
| Maccio et al. | SARS-CoV-2 leads to a small vessel endotheliitis in the heart | |
| Ferrer-Gómez et al. | Late cardiac pathology in severe covid-19. A postmortem series of 30 patients | |
| Lian et al. | Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1α-ADAM17 pathway✰ | |
| Lukito et al. | Mechanical circulatory support is associated with loss of platelet receptors glycoprotein Ibα and glycoprotein VI | |
| Won et al. | Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs | |
| Alexandru et al. | Vascular complications in diabetes: Microparticles and microparticle associated microRNAs as active players | |
| Bussani et al. | Persistent SARS‐CoV‐2 infection in patients seemingly recovered from COVID‐19 | |
| Bentzon et al. | Mechanisms of plaque formation and rupture | |
| Haeger et al. | Epithelial heparan sulfate contributes to alveolar barrier function and is shed during lung injury | |
| Pelliccia et al. | Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study | |
| Yunoki et al. | Relationship of thrombus characteristics to the incidence of angiographically visible distal embolization in patients with ST-segment elevation myocardial infarction treated with thrombus aspiration | |
| Haberecker et al. | Autopsy-based pulmonary and vascular pathology: pulmonary endotheliitis and multi-organ involvement in COVID-19 associated deaths | |
| Grupper et al. | Circulating galectin-3 levels are persistently elevated after heart transplantation and are associated with renal dysfunction | |
| Tsujino et al. | Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity | |
| Godement et al. | Neutrophil extracellular traps in SARS-CoV2 related pneumonia in ICU patients: the NETCOV2 study | |
| Rosenbaum et al. | Outcomes after cardiac transplant for wild type transthyretin amyloidosis | |
| Djohan et al. | Endothelial progenitor cells in heart failure: an authentic expectation for potential future use and a lack of universal definition | |
| Zhang et al. | Complement factor 3 could Be an independent risk factor for mortality in patients with HBV related acute‐on‐chronic liver failure | |
| Buschmann et al. | Body mass index (BMI) and its influence on the cardiovascular and operative risk profile in coronary artery bypass grafting patients: impact of inflammation and leptin | |
| Ganem et al. | Preoperative B-type natriuretic peptide, and not the inflammation status, predicts an adverse outcome for patients undergoing heart surgery | |
| van den Berg et al. | Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies | |
| Akkus et al. | Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission | |
| Feldmann et al. | Perioperative onset of acquired von Willebrand syndrome: Comparison between HVAD, HeartMate II and on-pump coronary bypass surgery |